GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (OTCPK:OXBDF) » Definitions » Debt-to-EBITDA

Oxford BioMedica (Oxford BioMedica) Debt-to-EBITDA : -0.49 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Oxford BioMedica Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oxford BioMedica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.6 Mil. Oxford BioMedica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $136.5 Mil. Oxford BioMedica's annualized EBITDA for the quarter that ended in Dec. 2023 was $-290.9 Mil. Oxford BioMedica's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.48.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Oxford BioMedica's Debt-to-EBITDA or its related term are showing as below:

OXBDF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.52   Med: -0.43   Max: 18.11
Current: -0.75

During the past 13 years, the highest Debt-to-EBITDA Ratio of Oxford BioMedica was 18.11. The lowest was -10.52. And the median was -0.43.

OXBDF's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs OXBDF: -0.75

Oxford BioMedica Debt-to-EBITDA Historical Data

The historical data trend for Oxford BioMedica's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Debt-to-EBITDA Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.88 3.31 0.28 -10.52 -0.75

Oxford BioMedica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 -6.74 -19.76 -1.68 -0.49

Competitive Comparison of Oxford BioMedica's Debt-to-EBITDA

For the Biotechnology subindustry, Oxford BioMedica's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Debt-to-EBITDA falls into.



Oxford BioMedica Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oxford BioMedica's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.625 + 136.461) / -188.124
=-0.75

Oxford BioMedica's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.625 + 136.461) / -290.942
=-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Oxford BioMedica  (OTCPK:OXBDF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Oxford BioMedica Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica (Oxford BioMedica) Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.